New research shows that a combination of the targeted agent rituximab and the chemotherapeutic drug fludarabine can produce long-term remissions in some chronic lymphocytic leukemia patients without increasing the risk of later therapy-related myelodysplastic syndrome. After nearly 10 years of follow-up, 13 percent of patients had remissions lasting more than seven years.